This Listing of Claims will replace all prior versions, and listings, of claims in this application:

Listing of Claims:

129. (Previously Presented) A composition comprising a pharmaceutically acceptable carrier and an effective amount of a pharmaceutically acceptable acid addition salt of triethylenetetramine and succinic acid.

130. (Previously Presented) The composition of claim 129 comprising from 50 mg to 500 mg of a pharmaceutically acceptable acid addition salt of triethylenetetramine and succinic acid.

131. (Previously Presented) The composition of claim 129 comprising from 50 mg to 450 mg of an acid addition salt of triethylenetetramine and succinic acid.

132. (Previously Presented) The composition of claim 129 comprising from 50-100 mg to about 400 mg of an acid addition salt of triethylenetetramine and succinic acid.

133. (Previously Presented) The composition of claim 129 comprising from 50-100 mg to about 300 mg of an acid addition salt of triethylenetetramine and succinic acid.

134. (Previously Presented) The composition of claim 129 comprising from 110 to 290 mg of an acid addition salt of triethylenetetramine and succinic acid.

135. (Previously Presented) The composition of claim 129 comprising from 120 to 280 mg of an acid addition salt of triethylenetetramine and succinic acid.

136. (Previously Presented) The composition of claim 129 comprising from 130 to 270 mg of an acid addition salt of triethylenetetramine and succinic acid.

137. (Previously Presented) The composition of claim 129 comprising from 140 to 260 mg of an acid addition salt of triethylenetetramine and succinic acid.

138. (Previously Presented) The composition of claim 129 comprising from 150 to 250 mg of an acid addition salt of triethylenetetramine and succinic acid.

139. (Previously Presented) The composition of claim 129 comprising from 160 to 240 mg of an acid addition salt of triethylenetetramine and succinic acid.

140. (Previously Presented) The composition of claim 129 comprising from 170 to 230 mg of an acid addition salt of triethylenetetramine and succinic acid.

141. (Previously Presented) The composition of claim 129 comprising from 180 to 220 mg of an acid addition salt of triethylenetetramine and succinic acid.

142. (Previously Presented) The composition of claim 129 comprising from 190 to 210 mg of an acid addition salt of triethylenetetramine and succinic acid.

143. (Previously Presented) The composition of claim 129 comprising from 50 mg to 100 mg of an acid addition salt of triethylenetetramine and succinic acid.

144. (Previously Presented) The composition of claim 129 wherein the amount of the acid addition salt of triethylenetetramine and succinic acid is selected from the group consisting of 50 mg, 110 mg, 120 mg, about 130 mg, 140 mg, and 150 mg.

145. (Previously Presented) A composition comprising a pharmaceutically acceptable carrier and a pharmaceutically acceptable acid addition salt of triethylenetetramine and succinic acid in an amount selected from the group consisting of 1.2 mg, 10 mg, 12 mg, 20 mg, 30 mg, and 40 mg.

146. (Currently Amended) The composition of any of claims 129-144 or 145, wherein said acid addition salt of triethylenetetramine and succinic acid is ~~purified~~ prepared using an acid which yields a physiologically acceptable salt.

147. (Previously Presented) The composition of claim 146, wherein said composition is in a form suitable for oral administration.

148. (Previously Presented) The composition of claim 147, wherein said form suitable for oral administration is a capsule.

149. (Previously Presented) The composition of claim 147, wherein said form suitable for oral administration is a tablet.

150. (Previously Presented) The composition of claim 149, wherein said tablet is an enteric-coated tablet.

151. (Previously Presented) The composition of claim 149, wherein said tablet is a layered tablet.

152. (Previously Presented) The composition of claim 147, wherein said form suitable for oral administration is a sustained release preparation.

153. (Previously Presented) The composition of claim 152, wherein said sustained release preparation is a delayed release preparation.

154. (Previously Presented) The composition of claim 152, wherein said sustained release preparation is a slow release preparation.

155. (Previously Presented) The composition of claim 152, wherein said sustained release preparation is a controlled release preparation.

156. (Previously Presented) The composition of claim 152, wherein said sustained release preparation is an extended release preparation.

157. (Previously Presented) The composition of claim 146, wherein said composition is in a form suitable for transdermal administration.

158. (Previously Presented) The composition of claim 146, wherein said composition is in a form suitable for transmucosal administration.

159. (Previously Presented) The composition of claim 146, wherein said composition is in a form suitable for administration as a suppository.

Claims 160 and 161 (Cancelled)

Claims 162 to 171 (Cancelled)

172. (New) The composition of claim 146 further comprising at least one agent which enhances bioavailability or absorption of the acid addition salt.

173. (New) A composition according to claim 172 wherein said agent increases blood flow.

174. (New) A composition according to claim 172 wherein said agent comprises a vasodilator.

175. (New) A composition according to claim 172 wherein said agent inhibits reverse active transport mechanisms.